2′‐ Fucosyllactose attenuates estrogen‐deficiency‐associated bone loss and intestinal dysfunction in ovariectomized rats
Journal of the Science of Food and Agriculture · 15.01.2027 · 107 (1) · 357-370
DOI: 10.1002/jsfa.70980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Science of Food and Agriculture, online erschienen am 14.08.2026. Verfasst von Shengpeng Su und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Engineering, Northwest A&F University, Yangling, China. Hauptthemen laut MEDLINE: Estrogens, Trisaccharides, Intestines, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Tang Scholar by Cyrus Tang Foundation, Shaanxi Postdoctoral Science Foundation.
Abstract (Originalsprache)
BACKGROUND Postmenopausal osteoporosis (PMO), driven primarily by estrogen deficiency, is the most prevalent form of osteoporosis and a major global health burden. Estrogen deficiency disrupts gut microbial homeostasis, compromises intestinal barrier integrity and promotes inflammatory bone loss partly through dysregulation of the osteoprotegerin (OPG)/receptor activator of nuclear factor‐κB ligand (RANKL) axis. However, the safety concerns and poor adherence associated with long‐term pharmacotherapy underscore the need for safer nutritional strategies. Here, we evaluated the protective effects of 2′‐fucosyllactose (2′‐FL), a natural milk oligosaccharide, against PMO using chondroitin sulfate (CS) as a comparator. RESULTS The results showed that 2′‐FL restored the balance of the OPG/RANKL axis, improved intestinal integrity and reduced inflammatory cytokine levels. Linear discriminant analysis effect size‐based analysis further indicated that 2′‐FL may reshape the gut microbiota by promoting the enrichment of selected beneficial microbial taxa, including Adlercreutzia , Gordonibacter and Akkermansia , at the same time as reducing the relative abundance of Ruminococcus and Prevotella under estrogen‐deficient conditions. Moreover, 2′‐FL exhibited comparable efficacy to CS in restoring bone homeostasis. CONCLUSION Collectively, these findings demonstrate that 2′‐FL alleviates both bone loss and intestinal dysfunction under estrogen‐deficient conditions. 2′‐FL improved bone microarchitecture, favourably modulated bone‐remodelling and intestinal barrier‐associated markers, reduced inflammation and concurrently altered gut microbial composition. © 2026 Society of Chemical Industry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science and Engineering, Northwest A&F University, Yangling, China.
- Mengniu Hi-Tech Dairy Product Beijing Co., Ltd., Beijing, China.
- Inner Mongolia Mengniu Dairy Industry Co., Ltd., Hohhot, China.
ORCID-Profile: Wentao Zhang
Förderung
- Tang Scholar by Cyrus Tang Foundation
- Shaanxi Postdoctoral Science Foundation
Zitieren
APA
Su, S., Yang, L., Li, S., Gou, Z., Sun, E., Shen, Q., Li, Z., Wang, L., He, Y., Wang, J., Zhang, W., Wang, C., & Liu, J. (2027). 2′‐ Fucosyllactose attenuates estrogen‐deficiency‐associated bone loss and intestinal dysfunction in ovariectomized rats. Journal of the Science of Food and Agriculture, 107(1), 357-370. https://doi.org/10.1002/jsfa.70980
Vancouver
Su S, Yang L, Li S, Gou Z, Sun E, Shen Q, et al. 2′‐ Fucosyllactose attenuates estrogen‐deficiency‐associated bone loss and intestinal dysfunction in ovariectomized rats. Journal of the Science of Food and Agriculture. 2027;107(1):357-370. doi:10.1002/jsfa.70980
BibTeX
@article{Su2027,
author = {Su, Shengpeng and Yang, Lin and Li, Shusen and Gou, Zhifei and Sun, Erna and Shen, Qiruonan and Li, Ziqiang and Wang, Lin and He, Yafei and Wang, Jianlong and Zhang, Wentao and Wang, Chenyuan and Liu, Julong},
title = {2′‐ Fucosyllactose attenuates estrogen‐deficiency‐associated bone loss and intestinal dysfunction in ovariectomized rats},
journal = {Journal of the Science of Food and Agriculture},
year = {2027},
volume = {107},
number = {1},
pages = {357--370},
doi = {10.1002/jsfa.70980}
}
EUVIMED